Monday was a big day for me.

After undergoing 36 consecutive weeks of Revlimid, Velcade, and dexamethasone therapy since my stem cell transplant, I was hoping that Monday would be the day I could officially begin my easier-to-tolerate maintenance regimen.

Combination therapy with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (Decadron), known as RVD, had been tough for me to take over the last few months.  My platelet and white blood cell counts had been low and continued to edge down.  I was sore and out-of-sorts.  My body was screaming …